S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
S&P 500   4,594.62 (-2.27%)
DOW   34,899.34 (-2.53%)
QQQ   391.20 (-1.90%)
AAPL   156.81 (-3.17%)
MSFT   329.68 (-2.44%)
FB   333.12 (-2.33%)
GOOGL   2,843.66 (-2.69%)
AMZN   3,504.56 (-2.12%)
TSLA   1,081.92 (-3.05%)
NVDA   315.03 (-3.58%)
BABA   133.35 (-2.32%)
NIO   39.99 (-3.45%)
CGC   11.69 (-1.52%)
AMD   154.81 (-1.89%)
GE   97.84 (-4.29%)
MU   83.42 (-3.24%)
T   24.22 (-1.02%)
F   19.75 (-2.47%)
DIS   148.11 (-2.13%)
ACB   6.79 (+0.15%)
AMC   37.63 (-3.24%)
PFE   54.00 (+6.11%)
BA   199.21 (-5.41%)
NASDAQ:ONTX

Onconova Therapeutics Stock Forecast, Price & News

$3.17
-0.12 (-3.65%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.13
$3.27
50-Day Range
$3.04
$6.30
52-Week Range
$2.89
$28.95
Volume
165,119 shs
Average Volume
1.94 million shs
Market Capitalization
$65.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.72
30 days | 90 days | 365 days | Advanced Chart
Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Onconova Therapeutics logo

About Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Headlines

Onconova Therapeutics (NASDAQ:ONTX) Announces Earnings Results
November 12, 2021 |  americanbankingnews.com
Recap: Onconova Therapeutics Q3 Earnings
November 11, 2021 |  benzinga.com
34 Stocks Moving In Friday's Mid-Day Session
September 24, 2021 |  msn.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONTX
Employees
12
Year Founded
N/A

Sales & Book Value

Annual Sales
$230 thousand
Book Value
$0.45 per share

Profitability

Net Income
$-25.16 million
Net Margins
-8,294.27%
Pretax Margin
-9,157.63%

Debt

Price-To-Earnings

Miscellaneous

Free Float
20,573,000
Market Cap
$65.88 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/11/2021
Today
11/26/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

489th out of 1,392 stocks

Pharmaceutical Preparations Industry

232nd out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

Is Onconova Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Onconova Therapeutics stock.
View analyst ratings for Onconova Therapeutics
or view top-rated stocks.

How has Onconova Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ONTX shares have decreased by 41.3% and is now trading at $3.17.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a drop in short interest in the month of October. As of October 29th, there was short interest totaling 438,200 shares, a drop of 52.6% from the October 14th total of 923,500 shares. Based on an average daily trading volume, of 1,930,000 shares, the days-to-cover ratio is presently 0.2 days.
View Onconova Therapeutics' Short Interest
.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Onconova Therapeutics
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) issued its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.11. Onconova Therapeutics had a negative net margin of 8,294.27% and a negative trailing twelve-month return on equity of 74.01%. During the same period last year, the firm earned ($0.45) earnings per share.
View Onconova Therapeutics' earnings history
.

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split before market open on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ONTX?

2 analysts have issued 12-month price targets for Onconova Therapeutics' shares. Their forecasts range from $11.00 to $12.00. On average, they anticipate Onconova Therapeutics' stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 262.8% from the stock's current price.
View analysts' price targets for Onconova Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the following people:

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (1.16%), Geode Capital Management LLC (0.85%), Pura Vida Investments LLC (0.72%), CVI Holdings LLC (0.62%), Morgan Stanley (0.22%) and Citadel Advisors LLC (0.00%). Company insiders that own Onconova Therapeutics stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin and Steven M Fruchtman.
View institutional ownership trends for Onconova Therapeutics
.

Which institutional investors are selling Onconova Therapeutics stock?

ONTX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Onconova Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Onconova Therapeutics stock?

ONTX stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Pura Vida Investments LLC, CVI Holdings LLC, Geode Capital Management LLC, Citadel Advisors LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Onconova Therapeutics stock in the last two years include Abraham N Oler, James J Marino, Jerome Groopman, Mark Patrick Guerin, and Steven M Fruchtman.
View insider buying and selling activity for Onconova Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $3.17.

How much money does Onconova Therapeutics make?

Onconova Therapeutics has a market capitalization of $65.88 million and generates $230 thousand in revenue each year. The biopharmaceutical company earns $-25.16 million in net income (profit) each year or ($1.2396) on an earnings per share basis.

How many employees does Onconova Therapeutics have?

Onconova Therapeutics employs 12 workers across the globe.

What is Onconova Therapeutics' official website?

The official website for Onconova Therapeutics is www.onconova.com.

Where are Onconova Therapeutics' headquarters?

Onconova Therapeutics is headquartered at 375 PHEASANT RUN, NEWTOWN PA, 18940.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at [email protected], or via fax at 267-759-3681.


This page was last updated on 11/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.